Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor:

David F. Adams,Mark S. Watkins,Luc Durette,Josée Laliberté,Félix Goulet,Elaine Debien,Kendall S. Frazier,Nacera Mellal,Liangfu Chen,Wei Shi,Roberta A. Thomas,Erding Hu

Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor:

2019

David F. Adams
Mark S. Watkins
Luc Durette
Josée Laliberté
Félix Goulet
Elaine Debien
Kendall S. Frazier
Nacera Mellal
Liangfu Chen
Wei Shi
Roberta A. Thomas
Erding Hu

Daprodustat (GSK1278863) is a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor in development for treatment of anemia of chronic kidney disease. Daprodustat’s biological activity s...

Keywords:

Cancer research
Internal medicine
Biology
Endocrinology
Daprodustat
Anemia
Kidney disease
Biological activity
HIF prolyl-hydroxylase inhibitor
Carcinogen
Hypoxia-inducible factors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations